GRI Bio director granted 4,527 options at $1.30 (08/13/2025)

GRI Bio, Inc. director Camilla V. Simpson was granted a stock option on 08/13/2025 to buy 4,527 shares of common stock at an exercise price of $1.30 per share.

Rhea-AI Filing Summary

GRI Bio, Inc. director Camilla V. Simpson was granted a stock option on 08/13/2025 to buy 4,527 shares of common stock at an exercise price of $1.30 per share. The option appears in Table II as a derivative security with an expiration date of 08/13/2035. The filing states the option vests in four equal quarterly installments and is fully vested on the first anniversary of the grant date. The reporting person is shown as a director and the Form 4 was signed by an attorney-in-fact on 08/14/2025.

Positive

• 4,527 stock options granted to director Camilla V. Simpson are disclosed, including exercise price $1.30 and expiration 08/13/2035
• Vesting schedule is specified: four equal quarterly installments, fully vested on the first anniversary of the grant

Negative

• None.

Insights

Securities Analyst

TL;DR: Director Camilla Simpson received a 4,527-option grant at $1.30, expiring 08/13/2035; vests over one year in quarterly installments.

The Form 4 documents a compensatory equity award to an insider, specifying the grant size, exercise price, and a ten-year expiration. For investors, this is a routine disclosure of insider compensation and ownership change. The grant increases the director's potential equity stake if exercised, and the vesting schedule ties realization to continued service during the next year. The filing contains clear transaction date and expiration details and is properly executed by an attorney-in-fact.

Corporate Governance Expert

TL;DR: Standard director option award recorded; vesting over four quarterly installments with a ten-year term is disclosed.

The disclosure is concise and follows Section 16 reporting requirements. The grant's vesting schedule—four equal quarterly installments culminating at one year—is explicitly stated, which clarifies when economic benefit accrues to the reporting person. The Form identifies the reporting person as a director and includes signature via attorney-in-fact. No amendments, other arrangements, or additional beneficial ownership details are provided in this filing.

Insider Trade Summary

Grant/Award: 4,527 shares

Grant/Award 1 txn

Insider SIMPSON CAMILLA V

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	4,527	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 4,527 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests in 4 equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Camilla V. Simpson report on Form 4 for GRI (GRI)?

The Form 4 reports a grant on 08/13/2025 of 4,527 stock options to purchase common stock at an exercise price of $1.30 with an expiration of 08/13/2035.

When do the options granted to Camilla V. Simpson vest?

The options vest in four equal quarterly installments and are fully vested on the first anniversary of the grant date.

How many shares underlying the derivative were reported as beneficially owned after the transaction?

The filing shows the reporting person beneficially owns 4,527 shares underlying the option following the reported transaction.

What is the relationship of the reporting person to GRI Bio, Inc.?

Camilla V. Simpson is reported as a director of GRI Bio, Inc.

Who signed the Form 4 filing and when was it signed?

The Form 4 was signed by Leanne Kelly, Attorney-in-Fact on 08/14/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2025 - 04:58 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SIMPSON CAMILLA V

(Last) (First) (Middle)

C/O GRI BIO, INC.

2223 AVENIDA DE LA PLAYA, SUITE 208

(Street)

LA JOLLA CA 92037

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GRI Bio, Inc. [ GRI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.3	08/13/2025		A		4,527		(1)	08/13/2035	Common Stock	4,527	$0	4,527	D

Explanation of Responses:

1. The stock option vests in 4 equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant.

Remarks:

	/s/ Leanne Kelly, Attorney-in-Fact	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.